After winning a grant, this French biotechnology company, pioneering exosome-based therapies for regenerative medicine applications, closed €10M in a new fundraising round.  

Contentlockr

Strasbourg, France-based EVerZom, a biotechnology company specialised in exosome-based therapies for regenerative medicine applications, raised €10M in funding.

The round was backed by Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by Audacia and Aloe Private Equity, Paris Business Angels, the Capital Cell platform, and several family offices.

This funding will help the French company start its first clinical trial of EVerGel in 2026, developed for the treatment of complex perianal fistulas in Crohn’s disease.

It plans to expand new uses for its exosomes in liver and skin treatments, and to increase its production of exosomes that meet GMP standards.

EVerZom: Developing exosome-based biotherapies

Founded by Jeanne Volatron and Nicolas Rousseau, EVerZom is developing a proprietary bioproduction platform and first-in-class therapeutic candidates based on mesenchymal stem cell-derived exosomes.

The strategy focuses on using exosomes and biomaterials together to improve treatments. The development pipeline includes EVerGel for Crohn’s complex perianal fistulas, with clinical trials starting in 2026.

Additionally, the French company is also developing Eviv, a preclinical candidate for Acute-on-Chronic Liver Failure (ACLF), a severe liver disease with no satisfactory treatment options other than transplantation.

The company’s ambition is to demonstrate that its exosome platform can be applied across multiple therapeutic areas with high unmet need, such as dermatology, cosmetics, and animal health.

There are also research projects in ophthalmology, regenerative medicine, and non-medical fields like cosmetics and veterinary care.

The EVerGel program combines exosomes from mesenchymal stem cells with a safe hydrogel.

This approach aims to help heal fistulas (an abnormal connection or tunnel between two body parts, such as an organ, blood vessel, or the skin) and improve patients’ quality of life by keeping the exosomes in place longer.

Early results from animal tests are promising — EVerGel healed 87.5 per cent of cases within four weeks, compared to only 12.5 per cent in the control group.

Around 2 million people worldwide have Crohn’s disease, claims the company.

This painful disease has a significant unmet medical need, with more than 60 per cent of patients lacking effective treatments.

The situation is worse since Alofisel was removed from the European market in December 2024 due to a failed clinical trial in the United States.

EVerZom has focused on developing an innovative platform for exosomes, backed by several patents.

This platform covers everything from selecting cells and producing exosomes to modifying and formulating them.

“With this fundraising, EVerZom is reaching a decisive milestone. Our ambition is to bring the therapeutic potential of exosomes to patients suffering from diseases with high unmet medical needs, where quality of life is severely impaired. Our priority is to achieve a first clinical proof-of-concept in Crohn’s perianal fistula and to establish the foundations of an industrial and partnership platform capable of driving the emergence of a new therapeutic class. We warmly thank our investors and partners for their trust and support,” states Jeanne Volatron, co-founder and CEO of EVerZom.

Grant under the France 2030

A French company received a grant under the France 2030 plan, awarded by Bpifrance in June 2025, for its project on biotherapies and bioproduction.

The €3M grant will help the company scale up its exosome bioproduction technology to 50 litres.

Svetoslava Georgieva, Chair of the EIC Fund Board, says, “We congratulate EVerZom on this successful fundraising. Their groundbreaking work in exosome-based therapies opens up new possibilities for treating a wide range of diseases and has the potential to transform the future of medicine. EIC Fund’s unique form of financing via EIC – combining grants and equity – is proving itself highly attractive to Europe’s most promising companies.”